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undergoing PCI in a large regional multicenter database 
Methods. Clinical procedural and outcome data were prospectively collected between 
July 1997 and June 2001 from 19,142 PCI in a consortium of 8 hospitals in Michigan. 
BMI was divided in 5 categories; 1) <20 (underweight), 2) 20-25 (normal), 3) 25-30 (over- 
weight); 4) 30-40 (obese) and 5) >40 (morbidly obese). 
Result,=. Of 18,778 patients for whom complete weight and height data were available, 
2.1% were classified as underweight, 36% as obese and 5.2% as morbidly obese. 
Underweight patients were older and had a higher percentage of women when compared 
to the general population (p<0.05), while obese patients were younger. Underweight sta- 
tus was associated with a higher incidence of transfusion, contrast nephropethy, emer- 
gency CABG and in-hospital mortality (all p<0.05). After adjustment for comorbiditias, 
underweight status was an independent predictor of in-hospital death (p<0.05). 
Variable (%) BMI <20 BM120-25 BM125-30 BM130-40 BMI>40 
Age (years) 68.6±12.06 66.6±12.5 63.5±11.9 60.9±11.1 57.2±10.6 
Female sex 60 37.5 27.3 32.4 51.5 
Peripheral vascular disease 18.4 12.9 9.9 8.7 8.8 
Diabetes 18.4 16.8 22.0 33.6 50.4 
Creatinine >2 rag/d4 8.5 5.3 3.3 2.9 4.2 
Transfusion 11.0 6.6 4.4 3.4 4.0 
Vascular Complications 3.1 2.4 1.97 2.03 2.05 
Contrast nephropathy 2.8 1.6 1.0 0.9 1.2 
Emergency CABG 1.8 0.85 0.78 0.80 0.72 
In-Hospital death 4.1 2.2 1.5 1.13 1.5 
Conclusion. Patients with low BMI are at increased risk of fatal and non-fatal complica- 
tions following PCIs. 
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Background: Post-procedure length of stay (LOS) is an important determinant of medi- 
cal costs following coronary stenting. Thus, identification of vadablas related to LOS may 
be important for quality improvement and cost reduction efforts. 
Methods: We evaluated 19,142 patients who underwent contemporary coronary stenting 
in a consortium of 8 hospitals. Predictors of log-transformed LOS were identified using 
multiple linear regression (MLR) modeling. Variables evaluated in sequence included 
pre-, intra- and post-procedure factors, and adverse outcomes. 
Resulta: In this large dataset, pre-procadure factors alone explained 20% of variability in 
post-procedure LOS (adjusted r square=0.197). The addition of procedural variables 
added little to the model (adjusted r square=0.22), while in the final model, addition of 
outcome variables further increased the overall predictive capacity (adjusted r 
squara=0.29). Female gender, advanced age, CHF, acute MI, cardiogenic shock, diabe- 
tes, emergent or urgent procedure, dialysis dependent renal failure, history of cardiac 
arrest, low ejection fraction and valvular heart disease were baseline independent clinical 
correlates of LOS (all p<O.05), while administration of pre and post procedure hepadn, of 
post procedure low molecular weight hepadn, use of Glycopretein itb/llla receptor block- 
ers, and use of intraaortic balloon pumps were care-process variables related to longer 
LOS (all p < 0.001). Vascular complication, unplanned CABG, blood transfusion, repeat 
procedures, contrast nephropathy, arrhythmias, post procedure stroke and MI were addi- 
tional outcome variables associated with increased LOS (all p_<0.01). 
Conclusion: 1) Baseline clinical characteristics are important correlates of LOS follow- 
ing coronary stenting 2) The identification of process of care variables and complications 
associated with increased LOS highlights important targets for quality improvement and 
cost reduction efforts. 
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TARGET investigators, Merck Research Laboratories, Blue Be//, Pennsylvania. 
Background: In the TARGET Study, patients received either tirofiban or abciximab dur- 
ing percutaneous coronary revascularization with the intent to perform stent. At 30 days, 
there were fewer major ischemic events among patients who received abciximab, but the 
treatment difference diminished and was not significant at 6 months. We assessed 
whether there were treatment differences in the 6-month hospitalization rate and total 
bed days for major ischemic events. 
Methods: Admission and discharge dates and data on repeat procedures (PCI and 
CABG) were collected for the initial hospitalization and for each subsequent hospitaliza- 
tion for an acute ischemic event (MI or repeat PCI or CABG) that occurred within 6 
months of randomization. The average remaining length of stay for the initial hospitaliza- 
tion following randomization, the number of hospitalizations for acute ischemic events, 
the total number of bed clays and the number of repeat procedures were estimated for 
the two treatments. Treatment differences and 95% bootstrap confidence intervals were 
obtained. 
Results: Results are shown in the table below. No significant differences were found. 
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Abciximab Tirofiban Difference (95% CI) 
(n=2411) (n=2398) 
Initial Hospitalizatiofl 
Repeat PCI/CABG (per 100 pts) 0.79 0.75 -0.04 ( -0.54; 0.42) 
Average Length of Stay (days) 1.57 1.60 0.03 ( -0.08; 0.15) 
6 Month (Post-Discharge) 
Hospitalizations (per 100 pts) 9.42 8.92 -0.50 ( -2.24; 1.21) 
Repeat PCI/CABG (per t 00 pts) 8.63 8.13 -0.49 ( -2.40; t .33) 
Total Bed Days (per t00 pts) 34.91 38.11 3.20 ( -7.61; 13.89) 
Conclusion: At 6 months, there were no significant differences in the rates of hospital- 
izations or total bed days for acute cardiac events. A 6-month cost analysis that includes 
both study medication and hospitalizations for acute cardiac events is planned. 
1073-168 International Differences in Cost, Medical Resource 
Utilization, and Clinical Event Rates in a Large 
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Conor O'Shaa. Joelle Y. Friedman, Karen Pieper, Kasem S. Akhras, Kevin A. Schulman, 
Duke Clinical Research/nstitute, Durham, North Carolina. 
Background: The extent to which international differences in the intensity of medical 
practice impact on patient outcomes is an important issue. We examined the medical 
costs and cardiovascular outcomes of 7232 patients undergoing coronary intervention at 
412 centers including North and South America and Europe in the EXCITE trial. 
Methods: Resources required to treat major cardiovascular events were recorded in the 
case report forms. Resource use data collected included information about hospital stay, 
and specific cardiovascular procedures. Costs for these resources were assessed at an 
individual patient level. Cost estimates for specific rasourcas were collected from cost 
analysts in each country. Unit cost estimates were converted to U.S. dollars using OECD 
Purchasing Power Parity (PPP) conversion rates. US costs were estimated by applying 
national average DRG reimbursements to hospitalizations and assigning costs to individ- 
ual CPT codes for both outpatient and inpatient procedures. 
Results: Costs were greatest in the US. In several countries, the 6 month composite of 
death and MI was significantly less than in the US, although these data have not been 
adjusted for differences in baseline risk. 
Conclusions: Even within the confines of a muiticanter clinical trial, there are significant 
international differences in resource utilization, medical costs and clinical event rates. 
These regional differences are likely to have important implications for trial design and 
sample-size calculations. 
Country (n) Cost ($) [Median (25, 75)] Death/MI at 6 Months 
Chile(61) 3459 (2189, 4626) 3.3% 
Mexico (142) 4030 (3279, 6760) 7.6% 
United Kingdom (222) 7608 (5683,11960) 4.0% 
Germany (350) 7760 (5988, 11866) 2.3% 
France (291) 9259 (8725, 17224) 3.8% 
United States (2871) 12779 (9681, 22460) 6.6% 
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The objective of our study was to evaluate practice and outcome variation with contem- 
porary percutaneous coronary interventions (PCI) as potential targets for quality 
improvement. 
Methods. Clinical, procedural and outcome data were prospectively collected between 
July 1997 and June 2001 from 19,142 PCI in a consortium of 8 hospitals in Michigan. 
Practice and outcome variation among the 8 hospitals were evaluated by calendar year 
(1998, 1999 and 2000). 
Results. Variation in resource utilization and outcomes are listed in the table. Data are 
expressed as percentage unless otherwise indicated. Numbers indicate average for the 
collaborative group, and lowest and highest frequencies. 
Variable Year 1998 Year 1999 
Pre procedure aspirin 
Use of Non Ionic Contrast 
Amount of Contrast/case 
(cc) 
Gp lib/Ilia receptor blocker 
use 
Post procedure heparin use 
Contrast nephropethy 
Transfusion 
Vascular Complications 
Emergency CABG 
Any CABG 
Year 2000 
Low, Average,High Low,Average,High Low,Average,High 
89.4 - 92.4 - 97.2 87.5 - 94.3 - 98.8 75.3 - 90.5 - 98.3 
17.7 - 68 - 100 29.6 - 78.9 - 100 37.9 - 84.8 - 99.8 
202 - 248 - 334 178 - 232 - 295 t 64 - 222 - 295 
13.4 - 31.3 - 48.4 32.3 - 43.6 - 82.1 49.6 - 61.7 - 91.8 
17.5 - 34.9 - 76.3 11.3 - 38.3 - 61.9 6.6 - 24.6 - 77.7 
0.34 - 0.9 - 2.44 0.11 - 0.52 - 1.55 0.22 - 0.72 - 1.8 
3.3 - 4.2 - 9.1 2.24- 4.46 - 6.8 2.24 - 4.7 - 8.61 
1.36 - 2.14 - 3.15 0.92 - 1.93 - 3.61 0.84 - 1.93 - 3.89 
0.30 - 1.0 - 1.67 0.16 - 0.64 - 1.44 0.22 - 0.7 - 1.3 
0.74 - 1.68 - 2.33 0.76 - 1.36 - 2.51 0.5 - 1.5 - 2.4 
Conclusion. 1 ) Substantial practice and outcome variation exists with contemporary PCI 
practice. 2) Analysis of this variation identifies potential targets for quality improvement 
programs in PCIs. 
